A possible role of vimentin on the cell surface for the activation of latent transforming growth factor-β  by Nishida, Yasutake et al.
FEBS Letters 583 (2009) 308–312journal homepage: www.FEBSLetters .orgA possible role of vimentin on the cell surface for the activation of latent
transforming growth factor-b
Yasutake Nishida a, Kenji Shibata a, Motoo Yamasaki a, Yasufumi Sato b, Mayumi Abe b,*
a Innovative Drug Research Laboratories, Research Division, Kyowa Hakko Kirin Co. Ltd., Tokyo 194-8533, Japan
bDepartment of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japana r t i c l e i n f o
Article history:
Received 24 November 2008
Revised 19 December 2008
Accepted 22 December 2008
Available online 31 December 2008
Edited by Masayuki Miyasaka
Keywords:
Latent TGF-b activation
Vimentin
LAP fragment
Avidin–biotin afﬁnity
Proteolysis0014-5793/$34.00  2008 Federation of European Bio
doi:10.1016/j.febslet.2008.12.051
* Corresponding author. Present address: Departm
Tokyo Medical Dental University Graduate School, Tok
3 5803 4679.
E-mail address: mayudnp@tmd.ac.jp (M. Abe).a b s t r a c t
Latent TGF-b (LTGF-b) has to be converted to active TGF-b for its activities. Previously, we reported
that certain fragments of latency associated peptide (LAP) augmented LTGF-b activation via increase
in binding of LTGF-b to the endothelial cell (EC) surface followed by cell-associated proteolysis. By
searching for EC membrane proteins crosslinked with the LAP fragment, we identiﬁed the molecule
bound to LAP fragment as vimentin. Moreover, the LAP fragment-induced LTGF-b activation was
attenuated by anti-vimentin antibody. These results indicate that binding of the LAP fragment to
vimentin on the cell surface is indispensable for LTGF-b activation by the LAP fragment.
Structured summary:
MINT-6806227: vimentin (uniprotkb:P48616) binds (MI:0407) to LAP (uniprotkb:P18341) by competition
binding (MI:0405)
MINT-6806183: LAP (uniprotkb:P18341) binds (MI:0407) to vimentin (uniprotkb:P48616) by cross-linking
studies (MI:0030).
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Transforming growth factor-b (TGF-b) is a multi-functional
cytokine involved in a wide variety of process. TGF-b is synthesized
and secreted as a latent complex composed of mature TGF-b, la-
tency associated peptide (LAP) and latent TGF-b (LTGF-b) binding
protein (LTBP) [1]. In order to execute its activities, TGF-b has to
be converted from a latent form to an active one, namely mature
TGF-b [1]. To date, various mechanisms for the activation of
LTGF-b have been proposed including shear forces [2]. However,
those can be mainly classiﬁed into two categories [1]. One is the
structural change of LTGF-b through interaction with other mole-
cules, such as thrombospondin-1 (TSP-1) [3] or integrin avb6 [4].
The other is the partial enzymatic cleavage or degradation of
LTGF-b [5]. Among several enzymes that activate LTGF-b, the
best-characterized one is plasmin, a serine protease, which re-
moves LAP from LTGF-b [5,6]. We have focused on the activa-chemical Societies. Published by E
ent of Nanomedicine (DNP),
yo 113-8549, Japan. Fax: +81tion mechanism involving in proteolysis on endothelial cell (EC)
[6–9].
Targeting of LTGF-b to cell surface of ECs, where protease activ-
ities exist, is one of the important steps for LTGF-b activation. We
developed a monoclonal antibody (mAb) against LAP (KM704).
KM704 inhibited the activation of LTGF-b by blocking its binding
to cells [7]. We assumed that the epitope of KM704 would be the
binding site of LTGF-b to cell surface. Therefore, we synthesized
several peptides containing the sequence of putative epitopes,
and examined if the peptides inhibit the binding of LTGF-b.
Surprisingly, some augmented its binding and enhanced LTGF-b
activation, although none of them inhibited [9]. Next, we synthe-
sized the relevant peptides supposed to be cleaved by plasmin
from LAP, since plasmin activity on the cell surface seems to be
necessary in the unique phenomenon [9]. One of the peptides,
Peptide-25 (Leu132 to Arg152 in the LAP molecule) bound to EC
surface, and increased binding of LTGF-b to there and the following
LTGF-b activation [9].
The purpose of this study was to identify the cell surface bind-
ing molecule of Peptide-25. We identiﬁed the molecule bound to
Peptide-25 as vimentin and conﬁrmed that Peptide-25 speciﬁcally
binds to vimentin protein on endothelial cell surface. Finally, we
demonstrated that vimentin is involved in the LTGF-b activation.lsevier B.V. All rights reserved.
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play a role in TGF-b activation by the LAP fragment.
2. Materials and methods
2.1. Materials
Peptide-25, Peptide-25N, N-terminally biotin-labeled peptide
and Peptide-21 were synthesized as previously described [9]. Bo-
vine aortic endothelial cells (BAECs) were cultured in Dulbecco’s
modiﬁed eagle medium containing 10% fetal bovine serum (FBS)
as previously described.
2.2. Cross-linking of Peptide-25N to the target molecule using BAECs
The conﬂuent monolayers were crosslinked with 100 lM Pep-
tide-25N using 2 mM Sulfo-EGS (Pierce Biotechnology, Rockford,
IL) and harvested in detachment buffer (DB; 0.25 M sucrose,
0.3 mM PMSF, 10 mM Tris, 1 mM EDTA, pH 7.4, 10 lg/mL of leu-
peptin, antipain, and pepstatin, 50 lg/mL aprotinin, 100 lg/mL
soybean trypsin inhibitor, 10 lg/mL bestatin and benzamidin
hydrochloride, and 300 lM PMSF). In some experiments, cross-
linking of Peptide-25N to the suspended cells was performed as
described above and the precipitated cells were suspended in DB.
Samples were stocked at 20 C. The cells stocked were thawed,
precipitated, and solubilized in reducing sample buffer for SDS–
PAGE. To purify the target molecule, the membrane fraction was
obtained in supernatant by solubilization in the buffer containing
8.5 M urea and 2% Nonidet P-40 and centrifugation.
2.3. Puriﬁcation of a target molecule by avidin–biotin afﬁnity
chromatography and SDS–PAGE
The membrane fraction was applied onto the avidin–biotin
afﬁnity chromatography column (Ultralink Immobilized Mono-
meric Avidin Gel, Pierce Biotechnology) equilibrated with starting
buffer (SB: 1.25 M urea, 2% NP-40, 125 mM NaCl, 10 mM Tris,
1 mM EDTA, pH 7.4). After washing the column with SB, strongly
bound molecules including the target molecule of Peptide-25N
were eluted in the buffer (2 M urea, 2% NP-40, 125 mM NaCl,
100 mM glycine, pH 2.8). The target molecules fractionated by
the avidin–biotin afﬁnity chromatography were precipitated by
incubation in cold acetone at 20 C over night, centrifuged, dried
in vacuo, and applied to SDS–PAGE. The bands corresponding to
the target complex containing Peptide-25N and to the co-eluted
protein were cut out and extracted in reducing sample buffer at
37 C over night. The purity of the target molecule preparation
was conﬁrmed by SDS–PAGE with Ag-staining using 2D-Silver
Stain II ‘‘DAIICHI” (Daiichi Pure Chemicals, Tokyo, Japan).
2.4. Detection of the complex containing Peptide-25N by avidin
staining
The proteins separated on SDS–PAGE were blotted onto a poly-
vinylidene ﬂuoride (PVDF) membrane (Millipore, Billerica, MA) and
the complex containing Peptide-25N was detected using avidin-
biotinylated horseradish peroxidase (HRP) complex solution (Elite
Vectastain ABC kit; Vector Laboratories, Burlingame, CA) and visu-
alized using ECL substrate solution and ECL ﬁlm (Amersham Biosci-
ences, Piscataway, NJ).
2.5. Amino acid sequencing of the co-eluted protein
The piece cut from the gel was applied to endoproteinase Asp-N
(Roche Diagnostics GmbH, Mannheim, Germany) digestion and theproduced peptide fragments were separated by RP-HPLC using a
MIC-15-03-MRP column (LC PACKING, San Francisco, CA) on
SMART system (Amersham). Fragments were applied to Edman
degradation by a LC system (492cLC, Applied Biosystems Japan,
Tokyo, Japan) and a protein sequencer (PPSQ-10, Shimadzu, Kyoto,
Japan). The co-eluted protein was identiﬁed by the N-terminal
sequence determination of the fragments followed by the compar-
ison with protein database SWISS-PROT.
2.6. Western blot analysis with anti-vimentin monoclonal antibodies
The complex containing Peptide-25N, and the co-eluted protein
extracted above were applied to SDS–PAGE followed by silver
staining or Western blot analysis with anti-vimentin monoclonal
antibody (mAb), clone V9 (ICN Pharmaceuticals, Aurora, OH),
HRP-linked whole anti-mouse IgG., ECL substrate solution, and
ECL ﬁlm (Amersham).
2.7. Binding assay of Peptide-25N to immobilized vimentin protein
The wells of 96-well black plates coated with 2 lg/mL of bovine
vimentin (PROGEN, Heidelberg, Germany) were blocked with PBS
containing 1% bovine serum albumin (PBS-BSA) for 2 h. Five micro-
gram per milliliters of anti-vimentin mAb VIM3B (IgG2a) (PRO-
GEN) or anti-a-actin mouse mAb clone ASM-1 (IgG2a) (PROGEN),
or vehicle and then Peptide-25N solution was added. The wells
were incubated with HRP-conjugated avidin (Amersham) in BSA-
PBS for 1 h. After each step, wells were washed. The wells were
incubated with ELISA Pico (Pierce) for 5 min. The chemilumines-
cence was detected using a plate reader (EnVision 2102 Multilabel
reader, Perkin Elmer, Waltham, MA). In some experiments, the sol-
uble vimentin was added in the presence of 1 lM Peptide-25N.
2.8. FACS analysis
To detect surface proteins, BAECs were harvested non-proteo-
lytically by cell dissociation buffer (GIBCO BRL, Carlsbad, CA) and
not permeabilized. The ﬁrst Ab was 5 lg/mL of anti-bovine vimen-
tin mAb clone VIM3B4 (IgG2a) or of mouse IgG2a and the second
Ab was 8 lg/mL of ﬂuorescein isothiocyanate (FITC)-conjugated
anti-mouse IgG2a Ab (Santa Cruz Biotechnology, Santa Cruz, CA).
Intact living cells which excluded propidium iodide were analyzed
by FACS Vantage (Becton Dickinson, Bedford, MA). The difference
in vimentin expression was evaluated by Kolmogrov–Smirnov test.
2.9. Binding assay of Peptide-25N to BAECs
Binding assays using BAECs were performed at 37 C as de-
scribed previously [9]. BAECs plated in a 96-well black plate were
preincubated with 5 lg/mL of anti-bovine vimentin mouse mAb
(clone VIM3B4) or with vehicle for 30 min. Cells were incubated
for 60 min with 100 lg/mL of biotin-labeled or unlabeled peptide
and then in HRP-conjugated streptavidin (Amersham) for further
30 min. the amount of bound peptide was detected by the addition
of ECL Western blotting detection reagent (Amersham) and mea-
sured by Luminescencer JNR (Atto Co., Tokyo, Japan).
2.10. Wound migration assay
Wound migration assays were performed as described previ-
ously [9]. Cells were incubated with 100 lg/mL of peptide in pre-
incubation (6 h) and in incubation (24 h) step after wounding. In
some experiments, 5 lg/mL of anti-vimentin mouse mAb clone
V9 (IgG1) (NeoMarkers, Fremont, CA) or of mouse IgG1 were added
in both steps.
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Fig. 2. Western blot analysis of the target fraction with anti-vimentin monoclonal
antibody. Proteins from band A (lanes 4, 5, 9, and 10) and B (lanes 1–3 and 6–8)
(Fig. 1B) were applied to SDS–PAGE followed by silver staining or Western blot
analysis using anti-vimentin mAb, clone V9. The amount corresponding to culture
area (cm2); 119 for lanes 1, 4, 6, and 9; 11.9 for lanes 2, 5, 7, 10; 1.19 for lanes 3 and
8. The complex of Peptide-25N and its crosslinked protein, and the co-eluted
protein were indicated by arrows A and B, respectively.
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The statistical signiﬁcance of differences in the data was evalu-
ated by use of analysis of variance (ANOVA) and P values were cal-
culated by Tukey’s method. For comparison of two groups, the
t-test was used. A value of P < 0.05 was accepted as statistically
signiﬁcant.
3. Results
To identify the membrane protein of binding partner for Pep-
tide-25, the cross-linking experiment combined with avidin stain-
ing was performed (Fig. 1) and revealed a speciﬁc band bound to
Peptide-25N in BAECs (the arrow in lane 1). This band was not de-
tected in the absence of Peptide-25 in spite of the presence of Sul-
fo-EGS, a cross-linker (lane 2). Therefore, we decided to purify and
identify this band as the target molecule bound to Peptide-25.
The membrane fraction was applied to avidin–biotin afﬁnity
chromatography and then SDS–PAGE (Fig. 1B). This target mole-
cule (band A) and a co-eluted protein (band B) were further puri-
ﬁed by SDS–PAGE. Firstly, the co-eluted protein with the
consistent molecular size of 55 kDa [10] was identiﬁed as vimentin
as a result of amino acid sequencing. To conﬁrm it, the bands A and
B were applied to Western blot analysis (Fig. 2). The band A (lanes
9 and 10) and the band B (lanes 6–8) reacted with an anti-vimentin
mAb (Fig. 2). This result was reproduced, when another anti-
vimentin mAb, clone VIM3B4, was used (data not shown). There-
fore, we concluded that the target molecule to which Peptide-
25N bound was vimentin (band B) and band A was the complex
of vimentin and Peptide-25N (about 2.7 kDa).
We found that binding of Peptide-25 to EC surface was the key
step for the augmented binding and activation of latent TGF-b [9].
To clarify whether vimentin is involved in this phenomenon, ﬁrstly
we performed the binding assay. Peptide-25N bound to the immo-
bilized vimentin protein in a dose dependent manner and anti-
vimentin mAb (IgG2a) inhibited it, whereas anti-a-actin mAb, an
irrelevant IgG2a, did not (Fig. 3A). Soluble vimentin suppressed
the binding of Peptide-25N in a dose-dependent manner
(Fig. 3B). These results indicate that vimentin could be a binding
partner of Peptide-25. Next, we conducted FACS analysis usingA B
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ist on cell surface (Fig. 4A). Moreover, anti-vimentin mAb signiﬁ-
cantly suppressed the binding of peptide-25 to cells (Fig. 4B).
These results indicate that Peptide-25 can directly and speciﬁcally
interact with vimentin on cell surface.
Finally, we performed wound migration assay which is widely
used to quantify activation of latent TGF-b [6,7,9,11,12]. Mature
TGF-b, an active form, shows inhibitory activity to EC migration.
Fig. 5 shows that Peptide-25 decreased the migration of ECs as
we previously reported [9]. This inhibitory activity of Peptide-25
was attenuated by anti-vimentin mAb. In contrast to Peptide-25,
Peptide-21 showed no signiﬁcant activity (Fig. 5). Peptide-21 (from200.0
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Fig. 3. Speciﬁc binding of Peptide-25N to immobilized vimentin protein. (A) Binding of Peptide-25N to immobilized vimentin protein was veriﬁed by adding anti-vimentin
mAb clone VIM3B, unrelated anti-a-actin mAb clone ASM-1 or vehicle. The data are shown as the mean and S.D. from four samples. *P < 0.005. (B) Binding of Peptide-25N to
immobilized vimentin protein was investigated by adding soluble vimentin. Background of the system is also shown. The data are shown as the mean and S.D. from four
samples.
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Fig. 4. Contribution of vimentin in binding of Peptide-25 to cell surface of BAECs. (A) The expression of vimentin on cell surface of BAECs was analyzed by FACS. A, Mouse
IgG2a as a negative control; B, anti-vimentin mAb (VIM3B4). The intensity of VIM3B4 (B) was signiﬁcantly higher than that of control (A) (P < 0.001). (B) Binding of biotin-
labeled (25N) or unlabeled (25U) peptide to BAECs was measured as described in Section 2. In some experiments, anti-vimentin mAb (VIM3B4) was added. The data are
shown as the mean and S.D. of eight samples. **P < 0.01.
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Fig. 5. Contribution of vimentin in LTGF-b activation by Peptide-25. To detect
activity of TGF-b, migration assay was performed in the presence of Peptide-25 or
Peptide-21 (negative control) as described in Section 2. In some experiments anti-
vimentin mAb or mouse IgG1 as a negative control was added. The data are shown
as the mean and SD of four samples. *P < 0.05 and **P < 0.01.
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binding to cells and activation [9]. Therefore, we concluded
that vimentin is involved in the latent TGF-b activation by
Peptide-25.4. Discussion
Vimentin is one of the cytoskeletal proteins classiﬁed as an
intermediate ﬁlament. However, vimentin is secreted by activated
macrophages in response to inﬂammatory signals for efﬁcient kill-
ing of microorganisms [13], suggesting the involvement of vimen-
tin in immune function. Macrophages are thought to be the
principle source of TGF-b during inﬂammatory response [14] and
active TGF-b is thought to be involved in various inﬂamed diseases
such as rheumatoid arthritis [15]. One of the mechanisms of LTGF-
b activation is partial enzymatic cleavage or degradation of LTGF-b
by such as plasmin, matrix metalloprotease, and calpain [5,6,8] and
the inﬂamed diseases show the elevated activity of those cell-asso-
ciated proteases [5,16]. We speculate the mechanism of LTGF-b
activation by the LAP fragments as following: (1) degradation of
LAP by elevated proteolysis on cell surface generates LAP frag-
ments, (2) active TGF-b is released from latent complex and exerts
its activities, (3) the LAP fragments bind to vimentin on cell sur-
face, (4) binding of LTGF-b to the cell surface is augmented by
the LAP fragment, and (5) the additional activation occurs. To our
knowledge, this is the ﬁrst report indicating that vimentin is in-
volved in the LTGF-b activation mechanism. The precise mecha-
nisms remain to be elucidated how the LAP fragments and
vimentin can work together to draw the LTGF-b complex to the cell
surface. It is critical to control the excessive activation of LTGF-b
for the treatment. We expect to develop a new type of TGF-b inhib-
itors through the study of activation of LTGF-b.
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